Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The SURMOUNT-5 trial showed tirzepatide produces about 47% more weight loss than semaglutide on average, which is 20.2% versus 13.7% body weight reduction over 72 weeks
J.TuckerK
The earliest projected approval date is mid to late next year, assuming all ongoing trials complete successfully
Manufacturers typically negotiate for favorable coverage on the formulary, which may include preferred tier status and few or no utilization management restrictions
US$ 21.45
US$ 24.04
US$ 24.58
